Recombinant SARS-CoV-2 Ad5 vectored vaccine

BIOLOGICAL2 trials

Sponsors

Jiangsu Province Centers for Disease Control and Prevention

Conditions

COVID-19

Phase 4

Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)

CompletedNCT04892459

Jiangsu Province Centers for Disease Control and PreventionCOVID-19

Start: 2021-05-25End: 2021-12-25Updated: 2022-03-31

Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults

CompletedNCT04952727

Jiangsu Province Centers for Disease Control and PreventionCOVID-19

Start: 2021-08-26End: 2022-05-15Updated: 2022-08-16

Related Papers

Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination.

2026-07-16

Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.

2026-01-22

Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously

2026-01-01

Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously

2026-01-01

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.

2023-06-2010 citations

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.

2023-03-0742 citations

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.

2022-01-27121 citations